PT-141 dosage and bremelanotide dosing

PT-141 dosage in the approved product label

The search question asks for a personal amount; the PT-141 evidence answers a product-specific question. The U.S. bremelanotide prescribing information describes an approved amount of 1.75 mg given subcutaneously, beneath the skin, for acquired, generalized HSDD in premenopausal women. In the Phase 3 trials, participants received 1.75 mg as needed over 24 weeks.

Those are label and study facts. They are not a dose recommendation, a schedule or injection instructions for an individual. I distrust a dose figure after it has lost the product and population that gave it meaning. A number copied onto a different preparation is no longer the same clinical proposition.

Premenopausal HSDD defines this dose entry.

The approved context is premenopausal women with acquired, generalized HSDD. Acquired means that desire was previously normal; generalized means that it extends beyond one situation or partner. The loss of desire causes marked distress. The label and review of medical treatment for female sexual dysfunction describe that particular indication.

There is no approved bremelanotide dose for men or for postmenopausal women in this record. I regard “for women” as incomplete language when it leaves out these boundaries. A woman’s age alone also does not establish the diagnosis, her cardiovascular health or whether treatment fits.

How much PT-141 to inject: identity comes before arithmetic.

The approved PT-141 injection comes as a filled product ready for use. Its label specifies a subcutaneous route. Earlier development included a nasal spray, and early pharmacology also studied intravenous administration; those routes did not become the approved form described here.

I would file a question about a research powder’s contents before any arithmetic about its amount. The black-market analytical study documents unregulated melanocortin products, while their identity, purity and concentration are not assured by the approved medicine’s label. This page supplies no reconstitution steps, syringe-unit conversion or injection technique.

A compounded prescription is another preparation again. Compounded preparations require a prescription and are not FDA-approved. Approval of the finished bremelanotide product does not transfer to every preparation with the same molecule’s name.

PT-141 duration: blood measurements and reported desire.

The question “how long does PT-141 last?” has a blood-concentration answer and a subjective-desire answer. The label gives a terminal half-life of approximately 2.7 hours, with a range of 1.9–4.0 hours, and a median time to peak blood concentration of approximately 0.5–1.0 hour. Half-life tracks declining drug concentration, while the duration of a subjective effect is measured separately.

In the 2022 study of 31 premenopausal women with HSDD, increased desire was reported for up to 24 hours. I won’t collapse those entries into a single duration. A blood-concentration measure and a reported change in desire answer different questions, and neither supplies a personal timing plan.

The same label contains cardiovascular contraindications and limits on use. Dose figures, cardiovascular exclusions and limits on use share the same label.